Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer

Affiliations

• ¹ Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: vsubbiah@mdanderson.org.
• ² Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, USA; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, USA.
• ³ Department of Anatomical Pathology, University of Texas MD Anderson Cancer Center, Houston, USA.
• ⁴ Department of Thoracic-Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.
• ⁵ Division of Radiology, University of Texas MD Anderson Cancer Center, Houston, USA.
• ⁶ Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA.
• ⁷ Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, USA; Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, USA.
• ⁸ Loxo Oncology at Lilly, Stamford, USA.
• ⁹ Loxo Oncology at Lilly, Stamford, USA. Electronic address: kevin@loxooncology.com.
• ¹⁰ Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, USA; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, USA. Electronic address: jie-wu@ouhsc.edu.